According to Eurekalert on September 4th, a crucial new review study conducted by a team of scientists, including researchers from the University of Massachusetts Amherst, identified three most effective smoking cessation strategies.
Varenicline, a prescription medication sold under brand names including Chantix and Champix; cytisine, a plant-based compound not widely available in the United States but sold as a natural health product (Cravv®) in Canada and Central and Eastern Europe, requiring a prescription in the UK; nicotine e-cigarettes. The review was conducted by the non-profit organization Cochrane Tobacco Addiction Group (CTAG) and published in the journal "Addiction," led by senior CTAG authors Jamie Hartmann-Boyce, Assistant Professor of Health Policy and Management at the University of Massachusetts Amherst School of Public Health and Health Sciences, and Jonathan Livingstone-Banks, researcher at the University of Oxford.
The review points out that the combination of these three best strategies with behavioral support, such as counseling, is most effective. Bupropion and Nicotine Replacement Therapy (NRT) are also effective, especially when NRT patches are combined with rapid forms such as gum.
The latest summary from CTAG highlights key findings from 14 Cochrane reviews published between 2021 and 2023. Three of the key reviews include:
Updated NRT review: It has been found that combining fast-acting forms of NRT (such as gum, lozenges, sprays) with NRT patches can help more people quit smoking compared to using a single form of NRT; E-cigarette review: As a dynamic systematic review, the latest update concludes that nicotine-containing e-cigarettes are more effective in increasing smoking cessation rates than NRT, with moderate certainty evidence showing higher cessation rates compared to nicotine-free e-cigarettes; 2023 Drug and E-cigarette Intervention Review: Covering all globally approved drugs and e-cigarettes for smoking cessation, the results show that nicotine e-cigarettes, varenicline, and bupropion have high certainty evidence as effective interventions, followed by combination NRT. An updated review on nicotine receptor partial agonists shows that in studies directly comparing bupropion and varenicline, the effectiveness of both in smoking cessation may not differ. The review includes 75 trials.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
